Patents by Inventor Benjamin SURATT

Benjamin SURATT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF SOLID ORGAN TRANSPLANT SUBJECTS WITH CD28/OX40 BISPECIFIC ANTIBODIES
    Publication number: 20260092113
    Abstract: Provided herein are methods for the treatment or prevention of solid organ transplant rejection in a subject in need thereof, comprising administering to the subject a multispecific binding proteins comprising (a) a first antigen binding domain (ABD) comprising an immunoglobulin single variable domain (ISVD) (e.g., VHH) with binding specificity to CD28; and (b) a second ABD comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL) with binding specificity to OX40.
    Type: Application
    Filed: June 13, 2025
    Publication date: April 2, 2026
    Inventors: Rami LISSILAA, Benjamin SURATT, Jessica VOSS
  • CD28/OX40 BISPECIFIC ANTIBODIES
    Publication number: 20250215102
    Abstract: Provided herein are multispecific binding proteins comprising (a) a first antigen binding domain (ABD) comprising an immunoglobulin single variable domain (ISVD) (e.g., VHH) with binding specificity to CD28; and (b) a second ABD comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL) with binding specificity to OX40. Also provided are methods of treating autoimmune diseases with said multispecific binding proteins.
    Type: Application
    Filed: December 11, 2024
    Publication date: July 3, 2025
    Inventors: Gerald BESTE, Yanik BRUYNOOGHE, Klervi DESRUMEAUX, Jennifer KUEHN, Charlotte LAHOUTE, Rami LISSILAA, Alessandro MASIERO, Sevim OEZGUER BRUEDERLE, Benjamin SURATT, Emmanuelle VIGNE, Jessica VOSS
  • CD28/OX40 bispecific antibodies
    Patent number: 12195546
    Abstract: Provided herein are multispecific binding proteins comprising (a) a first antigen binding domain (ABD) comprising an immunoglobulin single variable domain (ISVD) (e.g., VHH) with binding specificity to CD28; and (b) a second ABD comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL) with binding specificity to OX40. Also provided are methods of treating autoimmune diseases with said multispecific binding proteins.
    Type: Grant
    Filed: December 18, 2023
    Date of Patent: January 14, 2025
    Assignee: SANOFI
    Inventors: Gerald Beste, Yanik Bruynooghe, Klervi Desrumeaux, Jennifer Kuehn, Charlotte Lahoute, Rami Lissilaa, Alessandro Masiero, Sevim Oezguer Bruederle, Benjamin Suratt, Emmanuelle Vigne, Jessica Voss
  • CD28/OX40 BISPECIFIC ANTIBODIES
    Publication number: 20240209107
    Abstract: Provided herein are multispecific binding proteins comprising (a) a first antigen binding domain (ABD) comprising an immunoglobulin single variable domain (ISVD) (e.g., VHH) with binding specificity to CD28; and (b) a second ABD comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL) with binding specificity to OX40. Also provided are methods of treating autoimmune diseases with said multispecific binding proteins.
    Type: Application
    Filed: December 18, 2023
    Publication date: June 27, 2024
    Inventors: Gerald BESTE, Klervi DESRUMEAUX, Jennifer KUEHN, Charlotte LAHOUTE, Rami LISSILAA, Sevim OEZGUER BRUEDERLE, Benjamin SURATT, Emmanuelle VIGNE, Jessica VOSS